Francesca Ricci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca Ricci has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Alessandra Tedeschi
2 shared publicationsEnrica Morra
2 shared publications- Enrica Morra
Niguarda Ca’Granda Hospital
2 shared publications Marco Montillo
2 shared publications- Marzia Varettoni
Division of Hematology Fondazione IRCCS Policlinico San Matteo and University of Pavia Pavia Italy
2 shared publications - Silvio Veronese
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy
2 shared publications
Latest Publications
- 1 August 2013
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 13 (4) , 441-446
Should a Positive Direct Antiglobulin Test Be Considered a Prognostic Predictor in Chronic Lymphocytic Leukemia?
- 1 August 2013
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 13 (4) , 441-446
Should a Positive Direct Antiglobulin Test Be Considered a Prognostic Predictor in Chronic Lymphocytic Leukemia?
- 1 February 2011
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1) , 124-126
The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic Waldenström's Macroglobulinemia at Diagnosis
- 1 February 2011
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1) , 124-126
The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic Waldenström's Macroglobulinemia at Diagnosis
- Open Access
- 3 January 2011
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 3 (1) , e2011031
THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA
Secondary myelodisplasia (MDS) and acute myeloide leukaemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldesntrom Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkilator agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to nucleoside analogs therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylators. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed.
- 3 January 2011
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 3 (1) , e2011031
Open AccessTHERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA
Secondary myelodisplasia (MDS) and acute myeloide leukaemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldesntrom Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkilator agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to nucleoside analogs therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylators. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed.
- 1 October 2007
- Vol. 92 (10) , 1367-74
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Increased bone marrow (BM) angiogenesis has been demonstrated in several hematologic malignancies. BM angiogenesis is significantly decreased in patients with chronic lymphocytic leukemia (CLL) treated with fludarabine. The anti-angiogenic potential of alemtuzumab in CLL has not yet been investigated. We, therefore, evaluated BM angiogenesis in CLL patients treated sequentially with fludarabine and low doses of alemtuzumab. BM microvessel area was sequentially evaluated in 20 patients with advanced B-cell CLL who received, after a clinical response obtained with fludarabine-induction therapy, alemtuzumab, three times weekly for 6 weeks at a dose of 10 mg. The complete response rate improved from 45% after fludarabine induction to 90% after alemtuzumab consolidation. The extent of BM angiogenesis decreased continuously after either fludarabine or alemtuzumab (p=0.0002; Kruskal-Wallis test). Thirteen out of 20 (65%) patients changed from having a monoclonal to a polyclonal pattern of IgH sequences after alemtuzumab consolidation. A separate evaluation carried out in patients who achieved molecularly undetectable disease, as defined by polymerase chain reaction negativity, and in patients who remained with minimal residual disease after therapy with alemtuzumab showed a significant reduction of BM microvessel area only in the former (p=0.0002). Finally, molecular responses and a significant reduction of BM angiogenesis were more common in patients who received the cumulative planned dose of alemtuzumab (i.e.,180 mg) than in patients who received reduced doses (p=0.007 and p=0.0001, respectively). Overall, these data demonstrate a decrease in BM vascularity that characterized CLL patients who received low doses of subcutaneous alemtuzumab consolidation therapy after a clinical response to fludarabine induction therapy. Such a finding reflects, at least in part, the molecular response and cumulative dose of alemtuzumab.
- 1 October 2007
- Vol. 92 (10) , 1367-74
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Increased bone marrow (BM) angiogenesis has been demonstrated in several hematologic malignancies. BM angiogenesis is significantly decreased in patients with chronic lymphocytic leukemia (CLL) treated with fludarabine. The anti-angiogenic potential of alemtuzumab in CLL has not yet been investigated. We, therefore, evaluated BM angiogenesis in CLL patients treated sequentially with fludarabine and low doses of alemtuzumab. BM microvessel area was sequentially evaluated in 20 patients with advanced B-cell CLL who received, after a clinical response obtained with fludarabine-induction therapy, alemtuzumab, three times weekly for 6 weeks at a dose of 10 mg. The complete response rate improved from 45% after fludarabine induction to 90% after alemtuzumab consolidation. The extent of BM angiogenesis decreased continuously after either fludarabine or alemtuzumab (p=0.0002; Kruskal-Wallis test). Thirteen out of 20 (65%) patients changed from having a monoclonal to a polyclonal pattern of IgH sequences after alemtuzumab consolidation. A separate evaluation carried out in patients who achieved molecularly undetectable disease, as defined by polymerase chain reaction negativity, and in patients who remained with minimal residual disease after therapy with alemtuzumab showed a significant reduction of BM microvessel area only in the former (p=0.0002). Finally, molecular responses and a significant reduction of BM angiogenesis were more common in patients who received the cumulative planned dose of alemtuzumab (i.e.,180 mg) than in patients who received reduced doses (p=0.007 and p=0.0001, respectively). Overall, these data demonstrate a decrease in BM vascularity that characterized CLL patients who received low doses of subcutaneous alemtuzumab consolidation therapy after a clinical response to fludarabine induction therapy. Such a finding reflects, at least in part, the molecular response and cumulative dose of alemtuzumab.
- 1 March 2005
- Published by Elsevier in Clinical Lymphoma
- Vol. 5 (4) , 261-264
Clinical Characteristics and Outcome of Immunoglobulin M–Related Disorders
- 1 March 2005
- Published by Elsevier in Clinical Lymphoma
- Vol. 5 (4) , 261-264
Clinical Characteristics and Outcome of Immunoglobulin M–Related Disorders
- 1 September 2004
- Vol. 89 (9) , ECR35
Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
A 43 year-old woman presented with fever, abdominal pain, epato-splenomegaly, ascites, cholestasis, anemia, thrombocytopenia and previous diagnosis of sclerosing cholangitis based on liver biopsy and endoscopic retrograde cholangiopancreatography(ERCP). The bone marrow biopsy and the revision of liver biopsy using antitryptase stain diagnosed systemic mastocytosis. Because of the aggressive course of the disease the patient was treated with an acute myeloid leukaemia chemotherapy regimen without success.
- 1 September 2004
- Vol. 89 (9) , ECR35
Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
A 43 year-old woman presented with fever, abdominal pain, epato-splenomegaly, ascites, cholestasis, anemia, thrombocytopenia and previous diagnosis of sclerosing cholangitis based on liver biopsy and endoscopic retrograde cholangiopancreatography(ERCP). The bone marrow biopsy and the revision of liver biopsy using antitryptase stain diagnosed systemic mastocytosis. Because of the aggressive course of the disease the patient was treated with an acute myeloid leukaemia chemotherapy regimen without success.